Treatment-Resistant Depression in Argentina: results from a longitudinal analysis of the TRAL Study

Authors

  • Christian Lupo Médica psiquiatra; Directora CIAP, Rosario, Provincia de Santa Fe, Argentina
  • Gerardo García Bonetto Médico especialista en Psiquiatría, Instituto Médico DAMIC - Hospital Neuropsiquiátrico Provincia de Córdoba, Argentina
  • Ricardo Marcelo Corral Médico especialista en Psiquiatría; Presidente Fundación Estudio y Tratamiento de las Enfermedades Mentales, Buenos Aires, Argentina
  • Manuel Vilapriño Duprat Médico psiquiatra; Centro de Estudios Asistencia e Investigación en Neurociencias (CESASIN) – Mendoza, Argentina.
  • Hernán Alessandria Médico especialista jerarquizado en Psiquiatra, Fundador y Presidente de GlobalPsy, integración de redes y conocimientos en salud mental, Referente Disciplinar de Residencias de Psiquiatría de la Provincia de Buenos Aires, Investigador Principal Clínica Privada de Salud Mental Santa Teresa de Ávila, La Plata, Buenos Aires, Argentina
  • Gabriela Kanevsky Janssen-Cilag Farmacéutica S.A. https://orcid.org/0000-0001-7360-6941
  • Sergio Perocco Janssen Cilag Farmacéutica Ltda.

DOI:

https://doi.org/10.53680/vertex.v34i161.484

Keywords:

Treatment-resistant depression, Treatment Resistant Disorder, Treatment response, Standard of care, Patient reported outcomes, Argentina

Abstract

Literature concerning patients with Treatment-Resistant Depression (TRD) treatment response and patient report out- comes (PROs) -such as QoL or disability- in Argentina is scarce. In the scope of the Treatment-Resistant Depression in America Latina (TRAL) study which previous results highlighted the burden of TRD compared to non- RD patients as well as essential epidemiological data in the region, this paper reports on the outcomes of Standard-of- are (SOC) over a 1-year follow-up of TRD patients in the subsample for Argentina. From a sample of 220 MDD patients identified in 5 sites in Argentina, 72 patients were diagnosed with TRD. Exclusion criteria included patients with psychosis, schizophrenia, bipolar disorder, schizoaffective disorder, dementia, with severe chemical dependence or currently participating in another clinical trial. MADRS, PHQ-9 and PROs (EQ-5D and SDS) were used as outcomes. Patients’ mean age was 54.7 years and 70.3% of the patients were female. Around 61% of the patients achieved a response (reduction of MADRS score ≥ 50%), but over 33% did not achieve a remission (MADRS total score ≤12). Almost 67% of the patients still felt anxious/ depressed at the end of the study (EQ-5D), while disruption affected patients in diverse areas -71% in work/ school, 69.7% in social life/leisure and 66.6% in their family life/personal responsibilities. The burden of TRD is significant in Argentina, and more effort should be put in the implementation of treatment protocols with better outcomes.

Downloads

Download data is not yet available.

Published

2023-10-10

How to Cite

Lupo, C., García Bonetto, G., Corral, R. M., Vilapriño Duprat, M., Alessandria, H. ., Kanevsky, G. ., & Perocco, S. . (2023). Treatment-Resistant Depression in Argentina: results from a longitudinal analysis of the TRAL Study. Vertex Revista Argentina De Psiquiatría, 34(161, jul.-sept.), 32–44. https://doi.org/10.53680/vertex.v34i161.484

Issue

Section

Artículos

Most read articles by the same author(s)